FHTX FY 2022 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

FHTXFoghorn Therapeutics Inc.

$330M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M+1357.8% YoY

Gross Profit

$19M100.0% margin

Operating Income

-$117M-609.2% margin

Net Income

-$109M-566.3% margin

EPS (Diluted)

$-2.62

Cash Flow

Operating Cash Flow

$194M

Free Cash Flow

$192M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$405M

Total Liabilities

$405M

Stockholders' Equity

$112,000

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$1M	+1357.8%
Gross Profit	$19M	$1M	+1357.8%
Operating Income	-$117M	-$101M	-16.3%
Net Income	-$109M	-$101M	-7.5%